1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
4. TECHNOLOGICAL OUTLOOK
5. Africa Anti-Rheumatic Drugs Market by TYPE
5.1. Introduction
5.2. Non-Steroid Anti-Inflammatory Agents (NSAIDs)
5.3. Corticosteroids
5.4. Disease Modifying Anti-Rheumatic Drug (DMARDs)
5.4.1. Methotrexate
5.4.2. Sulfasalazine
5.4.3. Hydroxychloroquine
5.4.4. Leflunomide
5.4.5. Biologic DMARD
5.5. Others
6. Africa Anti-Rheumatic Drugs Market by Disease Type
6.1. Introduction
6.2. Rheumatoid Arthritis
6.3. Osteoarthritis
6.4. Gout
6.5. Lupus
6.6. Others
7. Africa Anti-Rheumatic Drugs Market by Distribution Channel
7.1. Introduction
7.2. Online
7.3. Offline
8. Africa Anti-Rheumatic Drugs Market by country
8.1. Introduction
8.2. South Africa
8.3. Nigeria
8.4. Algeria
8.5. Kenya
8.6. Tunisia
8.7. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. AbbVie Inc.
10.2. Pfizer Inc.
10.3. GlaxoSmithKline plc
10.4. F. Hoffmann-La Roche Ltd
10.5. Gilead Sciences, Inc.
10.6. Johnson and Johnson
10.7. Merck & Co.
10.8. Novartis AG
10.9. Amgen Inc
10.10. Emzor Pharmaceutical Industries Limited
10.11. Fidson Healthcare Plc
11. APPENDIX
11.1. Currency
11.2. Assumptions
11.3. Base and Forecast Years Timeline
11.4. Key benefits for the stakeholders
11.5. Research Methodology
11.6. Abbreviations
LIST OF FIGURES
LIST OF TABLES